ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 472

Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications

Marla Guzman, Meiqian Ma, B. Anne Eberhard and Joyce Hui-Yuen, Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Pediatric rheumatology and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:        

Libman-Sacks endocarditis (LSE) is a rare manifestation of pediatric-onset systemic lupus erythematosus (pSLE). It is difficult to differentiate LSE from infective endocarditis (IE) in immunosuppressed patients. Data remain scarce on the diagnosis of LSE and disease course. We aim to describe the diagnosis, evaluation and management of endocarditis in pSLE.

Methods:

A retrospective chart review was conducted of all patients who fulfilled ACR lupus classification criteria and were diagnosed with pSLE and either LSE or IE. Data were collected on demographics, laboratory results, echocardiogram findings, clinical features, and treatment. Descriptive statistics were used.

Results:

We describe 6 patients (4 females) with pSLE and endocarditis, with a mean age at diagnosis of 11.6 +/- 3.3 years (Table 1). Three patients were White, 2 Black, and 1 Asian. The mean disease duration from pSLE diagnosis to diagnosed cardiac involvement was 1.4 +/- 2.8 years. Four patients had biopsy-proven lupus nephritis. All patients had positive serologies for ANA and anti-dsDNA antibodies. Five patients had anti-cardiolipin (aCL) antibodies at pSLE diagnosis and 3 had aCL antibodies at endocarditis diagnosis. Four patients were on treatment with steroids, 2 were on hydroxychloroquine, and 2 were treatment-naive. One patient was treated with Cyclophosphamide, Rituximab, and plasmapheresis for pulmonary hemorrhage. The mean SLEDAI at diagnosis of endocarditis was 10.5 +/- 6.4. Two patients had baseline echocardiograms at the time of pSLE diagnosis; both were normal.

Two patients had LSE, with involvement of mitral and aortic valves on echocardiogram. Two patients had isolated IE without LSE, more commonly involving the tricuspid valve. Two patients were on antibiotics prior to obtaining blood cultures so overlying IE could not be ruled out. The only other concurrent clinical manifestation of lupus was arthritis in 2 patients.

No patients had an increase or change in immunosuppression specifically for treatment of LSE. Five patients received prophylactic anti-coagulation. One patient was placed on subacute bacterial endocarditis prophylaxis. The most severe complications were pulmonary embolus (one definite, one possible), distal emboli and Roth spots (2 patients).

Conclusion:

This is the largest case series of endocarditis in pSLE to date. Our data demonstrate endocarditis (LSE and/or IE) is more frequently diagnosed early in disease course, often in conjunction with other end-organ manifestations. As pSLE can have a more severe disease course than adult-onset SLE, our data suggest that endocarditis occurs in patients whose disease is either newly diagnosed or not well-controlled. Obtaining an echocardiogram at pSLE diagnosis with annual echocardiograms for surveillance may be useful. Anti-phospholipid antibodies play a role in LSE and should also be monitored.


Disclosure: M. Guzman, None; M. Ma, None; B. A. Eberhard, None; J. Hui-Yuen, None.

To cite this abstract in AMA style:

Guzman M, Ma M, Eberhard BA, Hui-Yuen J. Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/libman-sacks-endocarditis-in-pediatric-systemic-lupus-erythematosus-clinical-features-and-complications/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/libman-sacks-endocarditis-in-pediatric-systemic-lupus-erythematosus-clinical-features-and-complications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology